Investigating heart-related side effects in children with relapsed acute myeloid leukemia
Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications
This study is looking at how heart problems can affect kids who have had a relapse of acute myeloid leukemia after their chemotherapy, so we can better understand and manage these side effects during their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10887480 on NIH RePORTER |
What this research studies
This research focuses on understanding the heart-related side effects that can occur in children who have relapsed from acute myeloid leukemia (AML) after undergoing intensive chemotherapy. It aims to gather comprehensive data on the occurrence and progression of cardiotoxicity throughout the treatment process, rather than just during initial therapy. By analyzing the experiences of these patients, the research seeks to identify patterns and risks associated with different treatment protocols. This information will help improve the management of cardiotoxicity in pediatric AML patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years who have been diagnosed with relapsed acute myeloid leukemia.
Not a fit: Patients who are not diagnosed with acute myeloid leukemia or who are older than 11 years may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to better monitoring and management strategies for heart-related side effects in children undergoing treatment for relapsed AML.
How similar studies have performed: Previous research has shown that understanding treatment-related side effects can significantly improve patient care, indicating that this approach has the potential for success.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Getz, Kelly Diringer — University of Pennsylvania
- Study coordinator: Getz, Kelly Diringer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.